Taspoglutide

Taspoglutide

Taspoglutide

Chemical compound

Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche.[1] [2]

Quick Facts Clinical data, Routes ofadministration ...

Initially, phase II trials reported it was effective and well tolerated.[3]

Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])

In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]

As of May 2022 no new trials have been registered since 2010.[9]

Chemistry

Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

See also

References

  1. [1]
    "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". Business Wire. June 2008.
  2. [2]
    "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008. Archived from the original on 3 March 2016. Retrieved 13 January 2009.
  3. [3]
    Baggio LL, Drucker DJ (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide".
  4. [4]
    "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in the First Phase III Clinical Trial". October 2009. Archived from the original on 1 March 2010. Retrieved 12 February 2010.
  5. [5]
    "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". February 2010.
  6. [6]
    Clinical trial number NCT01051011 for "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy" at ClinicalTrials.gov
  7. [7]
    "Roche Halts Trials of Taspoglutide". 13 September 2010.
  8. [8]
    "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended". 13 September 2010.
  9. [9]
    Clinical studies of taspoglutide


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Taspoglutide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.